KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Share-based Compensation (2016 - 2025)

Resmed (RMD) has disclosed Share-based Compensation for 17 consecutive years, with $28.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation rose 27.85% year-over-year to $28.9 million, compared with a TTM value of $99.0 million through Dec 2025, up 16.95%, and an annual FY2025 reading of $91.7 million, up 14.31% over the prior year.
  • Share-based Compensation was $28.9 million for Q4 2025 at Resmed, up from $21.2 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $28.9 million in Q4 2025 and bottomed at $15.6 million in Q1 2021.
  • Average Share-based Compensation over 5 years is $19.5 million, with a median of $19.2 million recorded in 2023.
  • The sharpest move saw Share-based Compensation dropped 5.34% in 2022, then increased 27.85% in 2025.
  • Year by year, Share-based Compensation stood at $16.1 million in 2021, then rose by 2.25% to $16.5 million in 2022, then rose by 20.51% to $19.8 million in 2023, then rose by 14.08% to $22.6 million in 2024, then increased by 27.85% to $28.9 million in 2025.
  • Business Quant data shows Share-based Compensation for RMD at $28.9 million in Q4 2025, $21.2 million in Q3 2025, and $24.8 million in Q2 2025.